Orthobiologics Market by Products (Viscosupplementation Products, Synthetic Bone Substitutes, Demineralized Bone Matrices, Bone Morphogenic Protein, Allografts, and Stem Cells), Application (Osteoarthritis & Degenerative Arthritis, Spinal Fusion, Fracture Recovery, Soft-Tissue Injuries, and Maxillofacial & Dental Applications), End User (Hospitals & Orthopedic Clinics, Ambulatory Care Centers, Research & Academic Institutes, and Dental Clinics & Facilities)–Global Outlook & Forecast 2021-2031
GR - 772320Category: Biotechnology
Number of pages: 100-120 | Report Format: PDF | Published
date: 25 May, 2022
Historical Years – 2018 & 2019 | Base Year – 2020 | Forecasted Years – 2021 to 2031
Report Overview
The global orthobiologics market was pegged at ~US$ 5.44 billion in 2020 and is expected to witness a CAGR of ~5.4% during the forecast period.
Market Fundamentals
Orthobiologics are made from substances that are naturally found in the body or using synthetic substances. They are used by orthopedic surgeons for the rapid healing of injuries. They help in the healing of broken bones, tendons, injured muscles, joints, and ligaments. The term, "orthobiologics" is derived from the combination of two words- ortho referring to the bones, muscles, joints, and tendons, and biologics, which means substances that are naturally or synthetically derived that have properties for healing orthopedic tissues. Common orthobiologics include bone marrow concentrate, platelet-rich plasma, fat grafts, and birth tissues. Orthobiologics have played a key role in revolutionizing orthopedic care.
[88888]
Market Dynamics
Several factors contributing to the growth of orthobiologics market include the rising incidence of sports injuries and the increasing number of road accidents. The rising geriatric population globally and the growing number of people suffering from arthritis and other spine-related disorders are among the key factors boosting the growth of the global orthobiologics market. Moreover, the rising prevalence of arthritis and spinal disorders and the increasing awareness and preference for minimally invasive practices are also playing a pivotal role in propelling the global orthobiologics market growth. However, the high cost of biologics-based treatments and the chances of severe side effects are some of the factors hindering the orthobiologics market growth to a certain extent. The potential risk of infection, no osteogenic potential, or potential host rejection are some of the other disadvantages of using orthobiologics.
Market Ecosystem
The global orthobiologics market has been analyzed from four perspectives: Product, Application, End User, and Region.
Orthobiologics Market by Product
Based on product, the orthobiologics market has been segmented into viscosupplementation products, synthetic bone substitutes, demineralized bone matrices, bone morphogenic protein, allografts, stem cells, and others. Viscosupplementation products held the largest share of the orthobiologics market in 2020. The large market share of this segment can be attributed to the rising geriatric population, the rising incidence of arthritis, and the growth in lifestyle-related disorders such as obesity.
Orthobiologics Market by Application
Based on application, the market has been segmented into osteoarthritis & degenerative arthritis, spinal fusion, fracture recovery, soft-tissue injuries, and maxillofacial & dental applications. The osteoarthritis & degenerative arthritis segment held a large share of the global orthobiologics market. The rising incidence of arthritis, clinical advancements in osteoarthritis management methodologies with growing clinical evidence validating the efficacy of biologics in osteoarthritis treatment, and raising awareness of the use of orthobiologics for its treatment are likely to fuel the growth of this segment.
Orthobiologics Market by End User
[99999]
Based on end user, the market has been segmented into hospitals & orthopedic clinics, ambulatory care centers, research & academic institutes, and dental clinics & facilities. The hospitals & orthopedic clinics segment held the largest market share of the market in 2020. Hospitals & orthopedic clinics or centers being the first preference among the population suffering from joint, bone, or muscle-related problems is one of the major factors propelling the segmental growth. Furthermore, the presence of skilled professionals is also expected to boost the growth the market
Orthobiologics Market by Region
Regionally, the global orthobiologics market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America dominated the market for orthobiologics holding the largest market share in 2020. Factors driving the regional growth include the rising geriatric population, increasing incidence of arthritis, better reimbursement policies, and growing preference for minimally invasive procedures among the population. Moreover, the rising incidence of sports-related injuries and growing awareness of the use of orthobiologics are some of the other factors boosting the market growth in this region. Furthermore, the dense presence of the prominent players and new product launches have also played a pivotal role in propelling the growth of orthobiologics market in this region. The Asia-Pacific region is expected to witness the fastest growth in the market owing to rising in the geriatric population and a surge in obesity.
Competitive Landscape
Some of the prominent players operating in the global orthobiologics market include:-
Medtronic
DePuy Synthes
Stryker
Zimmer Biomet
Orthofix Medical Inc.
Smith & Nephew
Bone Biologics Corp.
Globus Medical, Bioventus
RTI Surgical, among others
Strategic Developments
In September 2021, Regenerative medicines company Locate Bio raised ã10 million of equity investment in a funding round co-led by existing shareholder Mercia Asset Management and new investor BGF. This funding is aimed to advance the regenerative medicine pipeline of orthobiologics
In September 2020, ESSKA (European Society for Sports Traumatology, Knee Surgery, and Arthroscopy) launched the "Orthobiologics Initiative" (ORBIT) to support a better knowledge of the full benefits of these therapies and establish a structured path to improve their use
In September 2020, Royal Biologics, an ortho-biologics company completed the acquisition of Fibrinet. The acquisition helped the company to add novel technologies to its portfolio of autologous and live cellular solutions to support orthopedic and spinal fusion
In June 2020, Bioventus launched its Signafuse Bioactive Bone Graft in a new strip format and also received 510(k) clearance. These strips consist of 55% bioglass by weight and have been shown to induce higher levels of osteoblast differentiation compared to other synthetic bone graft strips
In June 2020, Bioventus selected Bazis NN as its authorized distributor for Durolane, its single-injection joint-fluid osteoarthritis (OA) treatment
Report Scope
Report Attribute
Details
Market size value in 2020
USD 5.44 billion
Revenue forecast in 2031
USD 9.66 billion
Growth Rate
CAGR of 5.4% from 2021 to 2031
Base year for estimation
2020
Forecast period
2021-2031
Segments covered
Product, Application, and End User
Regional scope
North America, Europe, Asia Pacific, and the Rest of the World (ROW)
Frequently Asked Questions About This Report
arrow_forward The global orthobiologics market is expected to clock US$ 5.44 billion in 2020.
arrow_forward The global orthobiologics market is mainly driven by the rising prevalence of arthritis & spinal disorders, the increasing number of orthopedic surgeries, the growing incidence of sports injuries, rising geriatric population base, and increasing demand for minimally invasive surgeries
arrow_forward Medtronic, DePuy Synthes, Stryker, Zimmer Biomet, Orthofix Medical Inc., Smith & Nephew, Bone Biologics Corp., Globus Medical, Bioventus, and RTI Surgical, among others.
arrow_forward The growth rate of orthobiologics market is CAGR of ~5.4% between 2021-2031
arrow_forward North America dominated the orthobiologics market with the largest share, followed by the Asia Pacific.
arrow_forward The orthobiologics market is projected to reach US$ ~9.66 billion by 2031
1INTRODUCTION
1.1Market Ecosystem
1.2Geographic Scope
1.3Timeline Under Consideration
•Historical Years – 2018 & 2019
•Base Year – 2020
•Forecasted Years – 2021 to 2031
1.4Currency Used in the Report
2RESEARCH METHODOLOGY
2.1Research Approach
2.2Data Collection Methodology
2.3Data Sources
2.3.1Secondary Sources
2.3.2Primary Sources
2.4Market Estimation Approach
2.4.1Bottom Up
2.4.2Top Down
2.5Market Forecasting Model
2.6Limitations and Assumptions
3PREMIUM INSIGHTS
3.1Current Market Trend (COVID-19 Perspective)
3.2Key Players & Their Competitive Positioning (2020)
4MARKET DYNAMICS
4.1Drivers
4.2Restraints/Challenges
4.3Opportunities
5GLOBAL ORTHOBIOLOGICS MARKET - ANALYSIS & FORECAST, BY PRODUCT
5.1Viscosupplementation Products
5.2Synthetic Bone Substitutes
5.3Demineralized Bone Matrices
5.4Bone Morphogenic Protein
5.5Allografts
5.6Stem Cells
5.7Others
6GLOBAL ORTHOBIOLOGICS MARKET - ANALYSIS & FORECAST, BY APPLICATION
6.1Osteoarthritis & Degenerative Arthritis
6.2Spinal Fusion
6.3Fracture Recovery
6.4Soft-Tissue Injuries
6.5Maxillofacial & Dental Applications
7GLOBAL ORTHOBIOLOGICS MARKET - ANALYSIS & FORECAST, BY END USER
7.1Hospitals & Orthopedic Clinics
7.2Ambulatory Care Centers
7.3Research & Academic Institutes
7.4Dental Clinics & Facilities
8GLOBAL ORTHOBIOLOGICS MARKET - ANALYSIS & FORECAST, BY REGION
8.1North America Orthobiologics Market
8.1.1North America Orthobiologics Market, By Country
8.1.1.1US
8.1.1.2Canada
8.1.2North America Orthobiologics Market, By Product
8.1.3North America Orthobiologics Market, By Application
8.1.4North America Orthobiologics Market, By End User
8.2Europe Orthobiologics Market
8.2.1Europe Orthobiologics Market, By Country/Region
8.2.1.1Germany
8.2.1.2UK
8.2.1.3France
8.2.1.4Rest of Europe (ROE)
8.2.2Europe Orthobiologics Market, By Product
8.2.3Europe Orthobiologics Market, By Application
8.2.4Europe Orthobiologics Market, By End User
8.3Asia Pacific Orthobiologics Market
8.3.1Asia Pacific Orthobiologics Market, By Country/Region
8.3.1.1China
8.3.1.2Japan
8.3.1.3India
8.3.1.4Rest of Asia Pacific (RoAPAC)
8.3.2Asia Pacific Orthobiologics Market, By Product
8.3.3Asia Pacific Orthobiologics Market, By Application
8.3.4Asia Pacific Orthobiologics Market, By End User
8.4Rest of the World (RoW) Orthobiologics Market
8.4.1Rest of the World Orthobiologics Market, By Region
8.4.1.1Latin America
8.4.1.2Middle East & Africa
8.4.2Rest of the World Orthobiologics Market, By Product
8.4.3Rest of the World Orthobiologics Market, By Application
8.4.4Rest of the World Orthobiologics Market, By End User
9COMPANY PROFILES
9.1Medtronic
9.1.1Business Snapshot
9.1.2Products Offered
9.1.3Financial Details*
9.1.4Strategic Developments
9.2DePuy Synthes (Subsidiary of Johnson & Johnson)
9.3Stryker
9.4Zimmer Biomet
9.5Orthofix Medical Inc.
9.6Smith & Nephew
9.7Bone Biologics Corp.
9.8Globus Medical
9.9Bioventus
9.10RTI Surgical
*Insights on financial performance is subject to availability of information in public domain
Growth+Reports can now be customized as per client’s needs through GRG Health’s primary research and knowledge services capabilities
GRG Health’s unique GrowthMIX approach and robust research methodology helps us deliver unique & meaningful insights to our clients and uncover trends that won’t meet the standard approach
